NowWe know the dilution for Vivo acquisitions, 107,930,564 more share on the market. Since Mr. Pidduck is Medipharm CEO the stock went from $0,16 to $0,75 down more than 50%. the appeal on Hexo is due end of May. Now Mr Pidduck it is time to give a boost to that company you have change the orientation of the company the mix product sold the Australian business buy Vivo these are your decision, hopefully you will get rid of Vivo management, as you were saying in the conf. call 1 major drup development would change the company totally but this can take years so something has to happen in the meantime.